Figure 1From: Superior antigen-specific CD4+T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older The allocation and elimination of subjects during the course of the study. The reasons for elimination from the Total Vaccinated cohort (TVC) to give the per protocol immunogenicity cohorts are described to the left of each box. Safety was assessed in the TVC.Back to article page